News

The company intends to create a branded ingredient technology that will be introduced in early 2015 and will target the immune support and sport nutrition markets. After the

The company said that shipments of the product to its pharmacy customers have already started. Pennsaid (diclofenac sodium topical solution) 1.5% w/w is indicated to treat signs and

The US firm is focused on bringing new medicines for patients with central nervous system (CNS) disorders. With the acquisition, Otsuka will have access to Avanir’s clinical development

REOLYSIN’s primary mode of activity is to infect and selectively target tumours with activating Ras pathway mutations and/or over-expressions of Ras pathway elements including, amongst others, EGFR, BRAF,

This multicenter, Phase 2 clinical trial enrolled patients who have not responded well to existing anti-vascular endothelial growth factor (VEGF) therapies including Lucentis®, Avastin® and Eylea®. Top line

If approved, the latest regulatory submission will expand the indications for Imbruvica to a third type of blood cancer. Cilag, a Janssen Pharmaceutical member, and Pharmacyclics Switzerland are

Tarextumab is currently being evaluated in combination with chemotherapy in patients with previously untreated, extensive stage SCLC. The randomized, placebo-controlled Phase II trial will compare progression-free survival (PFS)

Zoptarelin doxorubicin, a novel synthetic peptide carrier linked to doxorubicin, is currently in a ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in endometrial cancer. Under the

Momenta recently announced the successful completion of Part A of the Phase 1/2 study and has initiated the Part B (Phase 2 proof-of-concept) study. The FDA’s Fast Track